Literature DB >> 27521036

[Guidelines for the radiotherapy of gliomas].

L Feuvret1, D Antoni2, J Biau3, G Truc4, G Noël2, J-J Mazeron5.   

Abstract

Gliomas are the most frequent primary brain tumours. Treating these tumours is difficult because of the proximity of organs at risk, infiltrating nature, and radioresistance. Clinical prognostic factors such as age, Karnofsky performance status, tumour location, and treatments such as surgery, radiation therapy, and chemotherapy have long been recognized in the management of patients with gliomas. Molecular biomarkers are increasingly evolving as additional factors that facilitate diagnosis and therapeutic decision-making. These practice guidelines aim at helping in choosing the best treatment, in particular radiation therapy.
Copyright © 2016 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Anaplastic glioma; Biologie moléculaire; Biomarkers; Glioblastoma; Glioblastome; Gliome anaplasique; Gliome de bas grade; Low-grade glioma; Radiation therapy; Radiothérapie

Mesh:

Year:  2016        PMID: 27521036     DOI: 10.1016/j.canrad.2016.07.008

Source DB:  PubMed          Journal:  Cancer Radiother        ISSN: 1278-3218            Impact factor:   1.018


  2 in total

1.  Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma.

Authors:  Loïg Vaugier; Loïc Ah-Thiane; Maud Aumont; Emmanuel Jouglar; Mario Campone; Camille Colliard; Ludovic Doucet; Jean-Sébastien Frenel; Carole Gourmelon; Marie Robert; Stéphane-André Martin; Tanguy Riem; Vincent Roualdes; Loïc Campion; Augustin Mervoyer
Journal:  Sci Rep       Date:  2021-11-11       Impact factor: 4.379

2.  Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.

Authors:  J Biau; E Chautard; E De Schlichting; G Dupic; B Pereira; A Fogli; M Müller-Barthélémy; P Dalloz; T Khalil; A F Dillies; X Durando; C Godfraind; P Verrelle
Journal:  Radiat Oncol       Date:  2017-12-06       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.